Presentations and videos

Minimal residual disease in Myeloma Session 1
Minimal residual disease in Myeloma Session 2
Improving Survival in Multiple Myeloma
What’s new in Myeloma Treatment: a New Zealand Perspective
CAR T-cell Therapy: a New Frontier in Blood Cancer Treatment
Four Decades of Myeloma – Ken Romeril

Research and articles

Multiple Myeloma Research Review

Highlights include: • Increased novel agent access in NZ improved MM survival • Pomalidomide-based regimens for relapsed/refractory MM • Daratumumab, lenalidomide + dexamethasone for untreated myeloma Download here: Multiple Myeloma...
Continue Reading

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry

Renal impairment (RI) is a poor prognostic factor in patients with multiple myeloma (MM). Despite improvements in survival with the introduction of novel therapies in recent years, RI remains one...
Continue Reading

Frontline treatment of elderly non transplant-eligible multiple myeloma patients using CyBorD with or without thalidomide-based consolidation: a retrospective multi-centre analysis of real-world data

Bortezomib in combination with cyclophosphamide and dexamethasone (CyBorD, is a well-established frontline chemotherapy regimen for patients with multiple myeloma, but prospective data on elderly non-transplant eligible patients is limited. A...
Continue Reading

The Burden of Myeloma Reports

The Burden of Multiple Myeloma: A study of the human and economic costs of myeloma in New Zealand
The Way Forward


Patients’ Perspectives

Development and diagnosis of multiple myeloma

Multiple myeloma treatment options and pathways